New hope for patients with rare brain lining cancer spread

NCT ID NCT05598853

Ongoing Disease control Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new way to give immunotherapy drugs (nivolumab and ipilimumab) for patients with lung cancer or melanoma that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). The drugs are given both directly into the spinal fluid and through a vein. The goal is to find the safest dose and see if this approach can control the disease. The study involves 26 participants and is currently active but not recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma Meningeal Carcinomatosis metastatic melanoma neoplastic meningitis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEPTOMENINGEAL METASTASIS MELANOMA STAGE IV NON-SMALL CELL LUNG CANCER STAGE IV

Contacts and locations

Locations

University Hospital Basel

Basel, Switzerland
University Hospital Geneva

Geneva, Switzerland
University Hospital Zurich

Zurich, Canton of Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.